News & Views | Published:


Walking over the inflammasome

The NLRP3 inflammasome contributes to pathogenic inflammation in a broad range of diseases, making it a highly relevant drug target. Two studies published in this issue found an inhibitor of NLRP3 inflammasome activation to directly bind NLRP3 within its central NACHT domain, interfering with ATP hydrolysis and structural changes critical for NLRP3 oligomerization and subsequent inflammasome formation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Martinon, F., Mayor, A. & Tschopp, J. Annu. Rev. Immunol. 27, 229–265 (2009).

  2. 2.

    Coll, R. C. et al. Nat. Chem. Biol. (2019).

  3. 3.

    Tapia-Abellán, A. et al. Nat. Chem. Biol. (2019).

  4. 4.

    Duncan, J. A. et al. Proc. Natl. Acad. Sci. USA 104, 8041–8046 (2007).

  5. 5.

    Brydges, S. D. et al. Immunity 30, 875–887 (2009).

  6. 6.

    Shao, B. Z., Xu, Z. Q., Han, B. Z., Su, D. F. & Liu, C. Front Pharmacol. 6, 262 (2015).

  7. 7.

    Perregaux, D. G. et al. J. Pharmacol. Exp. Ther. 299, 187–197 (2001).

  8. 8.

    Coll, R. C. et al. Nat. Med. 21, 248–255 (2015).

  9. 9.

    van Hout, G. P. et al. Eur. Heart J. 38, 828–836 (2017).

  10. 10.

    Jiang, H. et al. J. Exp. Med. 214, 3219–3238 (2017).

Download references

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Olaf Groß.

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Fig. 1: MCC950 action on NLRP3.